Scientific considerations for global drug development

Affiliations

• ¹ Department of Bioengineering and Therapeutic Sciences, University of California, San Francisco, San Francisco, CA, USA.
• ² Medicines and Health Technologies Unit, Department of Health Systems and Services, Pan American Health Organization, Regional Office of the World Health Organization, Washington, DC, USA.
• ³ Global Health, Bill and Melinda Gates Foundation, Seattle, WA, USA.
• ⁴ Department of Pharmaceutics, University of Nigeria, Nsukka, Enugu State, Nigeria.
• ⁵ Food and Drugs Authority, Accra, Ghana.
• ⁶ Sinovant Sciences Co., Shanghai, China.
• ⁷ School of Pharmaceutical Sciences, Tsinghua University, Beijing, China.
• ⁸ Gladstone Institute of Cardiovascular Disease, San Francisco, CA, USA.
• ⁹ Pharmacy Board of Sierra Leone, Freetown, Sierra Leone.
• ¹⁰ Department of Clinical Pharmacology and Therapeutics, Seoul National University College of Medicine and Hospital, Seoul, Republic of Korea.
• ¹¹ Department of Transdisciplinary Studies, Graduate School of Convergence Science and Technology, Seoul National University, Suwon, Republic of Korea.
• ¹² World Health Organization, Geneva, Switzerland.
• ¹³ NDA Partners LLC, San Luis Obispo, CA, USA.
• ¹⁴ Pharmaceuticals and Medical Devices Agency, Tokyo, Japan.
• ¹⁵ Center for Biologics Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD, USA.
• ¹⁶ Departments of Bioengineering and Genetics, Stanford University, Stanford, CA, USA.
• ¹⁷ Department of Bioengineering and Therapeutic Sciences, University of California, San Francisco, San Francisco, CA, USA. [email protected].
• ¹⁸ Departments of Medicine and Molecular Pharmacology, Stanford University School of Medicine, Stanford, CA, USA.